Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

5(62.5%)

Phase 2

3(37.5%)

8Total

Phase 1(5)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05957081Phase 1Recruiting

Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309

Role: lead

NCT05953012Phase 1Completed

Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration

Role: lead

NCT04986852Phase 2Terminated

Olinvacimab With Pembrolizumab in Patients With mTNBC

Role: lead

NCT03856099Phase 2Terminated

TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

Role: lead

NCT03722342Phase 1Unknown

TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma

Role: lead

NCT03720431Phase 1Unknown

TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer

Role: lead

NCT03033524Phase 2Completed

Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma

Role: lead

NCT01660360Phase 1Completed

Phase I Trial of Tanibirumab in Advanced or Metastatic Cancer

Role: lead

All 8 trials loaded